Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Altium Capital Management LLC

Altium Capital Management LLC increased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 153.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 175,000 shares of the company's stock after purchasing an additional 106,000 shares during the period. Altium Capital Management LLC owned approximately 0.43% of Keros Therapeutics worth $2,770,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. AlphaQuest LLC increased its stake in Keros Therapeutics by 469.0% during the 4th quarter. AlphaQuest LLC now owns 3,596 shares of the company's stock worth $57,000 after buying an additional 2,964 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Keros Therapeutics during the fourth quarter worth $90,000. Exchange Traded Concepts LLC acquired a new stake in shares of Keros Therapeutics in the fourth quarter valued at $99,000. CANADA LIFE ASSURANCE Co raised its stake in shares of Keros Therapeutics by 207.8% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 7,371 shares of the company's stock valued at $116,000 after acquiring an additional 4,976 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in Keros Therapeutics by 19.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,589 shares of the company's stock worth $136,000 after purchasing an additional 1,372 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on KROS shares. Scotiabank decreased their price objective on Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a research note on Thursday, January 16th. Truist Financial decreased their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Oppenheimer lowered their price target on shares of Keros Therapeutics from $63.00 to $23.00 and set an "outperform" rating for the company in a report on Thursday, January 16th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Finally, Piper Sandler lowered their target price on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a research note on Friday, January 17th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.33.

Insiders Place Their Bets

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the firm's stock in a transaction that occurred on Wednesday, April 9th. The shares were purchased at an average price of $10.13 per share, with a total value of $9,464,033.54. Following the completion of the acquisition, the insider now owns 4,392,737 shares in the company, valued at approximately $44,498,425.81. This represents a 27.01 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.90% of the stock is currently owned by insiders.

Keros Therapeutics Trading Up 2.1 %

Shares of Keros Therapeutics stock traded up $0.29 on Wednesday, hitting $14.18. The stock had a trading volume of 371,089 shares, compared to its average volume of 788,265. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The company's 50 day moving average price is $11.33 and its 200 day moving average price is $28.60. The stock has a market cap of $575.17 million, a price-to-earnings ratio of -2.72 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.36) by $0.22. The company had revenue of $3.04 million during the quarter, compared to analysts' expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. Analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.